spacer
home > epc > autumn 2003 > eea - an overview of requirements impacting industry
PUBLICATIONS
European Pharmaceutical Contractor

EEA - An Overview of Requirements Impacting Industry

Pharmacovigilance requirements in the EU are laid down in a variety of different documents, applicable according to the status and route of authorisation (such as pre- or post-approval, centrally or nationally approved). As it can be difficult for experienced personnel in this field, yet alone a newcomer, to digest these overlapping and detailed requirements, this article provides an overview of the reporting requirements applicable to the Marketing Authorisation Holder (MAH); gives sources for further information; and reviews possible changes arising as part of the current legislative review and as the EU moves towards enlargement.

The Basic Framework

Pharmacovigilance requirements in the EU are laid down in EU Regulations (540/95 (1) and 2309/93 (2), EU Directives 65/65 (3), 75/319 (4), 2000/38 (5) and 2001/83 (6)) and EU Guidelines (for example Notice to Marketing Authorisation Holders: Volume 9 - Pharmacovigilance Guidelines (7). There are also several policy papers relating to more specific functions, for example the concept paper on monitoring compliance (CPMP (Committee for Proprietary Medicinal Products) /PhVWP (Pharmacovigilance Working Party)/1618/01 (8)) and the EMEA (European Medicines Evaluation Agency) policy paper on electronic transmission (EMEA/H/5255/01 (9)). In addition, the EU Clinical Trials Directive (2001/20/EC (10)) lays down the basis for reporting from the clinical study environment, with relevant guidances currently being finalised.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Margaret Walters, Director of Pharmacovigilance at Merck Sharp & Dohme

Margaret Walters is currently Director of the European Office of Pharmacovigilance for Merck Sharp & Dohme Ltd. She has more than 16 years' experience in many areas of pharmacovigilance along with a further 10 years in basic research at Wellcome. Margaret is a member of the EFPIA Pharmacovigilance Ad Hoc group, co-chairs the PhRMA (EU) Pharmacovigilance team, is active in the EMEA/EFPIA Joint Working Party on Electronic Submissions and was part of the original (pre-ICH) MCA MedDRA Working Party.

She is also the author of several papers and her academic links include acting as External Adviser to the Postgraduate Diploma in Pharmacovigilance at the University of Hertfordshire.

spacer
Margaret Walters
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement